Rejuvenate Bio

Rejuvenate Bio is a biotechnology company developing novel gene therapy solutions to treat age-related diseases in both animals and humans. Their lead product, RJB-01, is a combination liver-directed adeno-associated virus (AAV) gene therapy that expresses the secreted factors FGF21 and sTGFβR2. This therapy has demonstrated the ability to increase heart function, decrease damage, and provide metabolic benefits in animal models of heart failure, obesity, and type II diabetes.

RJB-01 is initially being evaluated for the treatment of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) and Familial Partial Lipodystrophy (FPL) in humans. Concurrently, a canine version of RJB-01 is being developed in partnership with Phibro Animal Health for the treatment of Mitral Valve Disease (MVD) in dogs.

Rejuvenate Bio's technology originated from research conducted at Harvard Medical School, where it was shown to reverse age-related conditions such as obesity, type II diabetes, heart failure, and renal failure in mice. The company has secured exclusive worldwide licensing rights from Harvard University to commercialize this gene therapy platform.

In addition to RJB-01, Rejuvenate Bio is developing RJB-0402, a liver-targeting AAV vector-based gene therapy that drives overexpression of FGF21. preclinical data has demonstrated RJB-0402's efficacy in a mouse model of Arrhythmogenic Cardiomyopathy (ACM), improving cardiac function, preserving cardiac structure, and reducing premature ventricular contractions. The initial clinical study for RJB-0402 will focus on patients with Desmoplakin-related ACM at high risk of life-threatening ventricular arrhythmias and sudden cardiac death.

Furthermore, Rejuvenate Bio has reported groundbreaking research in the journal Cellular Reprogramming, demonstrating that AAV-mediated gene therapy delivering the Yamanaka factors OSK (OCT4, SOX2, and KLF4) extended median remaining lifespan by 109% in aged mice while reversing age-related changes and improving health parameters.